Another Androgenic Agent (VRaA)
Phase 1Small molecule
Another Androgenic Agent (VRaA) is one of 26 small molecule programs targeting Ovarian Reserve. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Ulipristal Acetate
AbbVieApproved
Folvite
Eli LillyPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Ovitrelle
Merck & Co.Approved
Human Menopausal Gonadotropin
EMD SeronoApproved
Buserelin
NNCIC Clinical Trials Group
Approved
Dehydroepiandrosterone
IInflabloc Pharmaceuticals
Phase 3
Trelstar
OOncoVerity, Inc.
Phase 2
Myoinositol
SSohag University
Phase 3
Dienogest
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLaboratorios Andromaco S.A.